T32-supported Immunology and Rheumatology Postdoctoral Fellows will undertake two years of training in either translational research in clinical immunology or in clinical investigation. Applicants for T32 support will be M.D., Ph.D. or M.D./Ph.D. degree holders. Candidates for postdoctoral fellowships will be reviewed and selected by a Postdoctoral Committee composed of representatives of the two Rheumatology Divisions. The clinical years of postdoctoral fellowship in rheumatology for MDs, not covered by T32 funding will predominantly consist of attendance at outpatient clinics, as well as inpatient consulting. Following clinical training, trainees will select one of two Research Tracks for their T32 training: (i.) The Clinical Immunology Translational Research Track (Track 1);or (ii.) The Clinical Investigation (Track 2). The training in Track 1 will be available for those fellows interested in pursuing translational research in clinical immunology and will be supplemented with required and recommended coursework. A two-year training program in Track 2 can lead to a Master's of Science Degree, administered through the Department of Health Research and Policy. It is our belief that such formal training is important for trainees who pursue a career in clinical research, to provide a foundation in the fundamentals of clinical trial design, bioethics, data analysis, and other important issues in clinical research. For all trainees in both Tracks, attendance will be required at weekly lectures in rheumatic diseases, as well as a series of lectures on Responsible Conduct of Research. Postdoctoral trainees are expected to attend weekly Immunology Grand Rounds, Journal Club meetings, the weekly Immunology Seminar Series, and the Annual T32 and Immunology Retreats during all years of training. This will provide interactions between the rheumatology fellows and the many other immunology fellows and students involved in research endeavors at Stanford. In the T32-supported years, MD postdoctoral fellows will attend clinic one or two half-days per week, as well as regular research meetings determined by their individual preceptors. We will leverage Stanford's rich environment to provide many additional opportunities for trainees interested in immunology, proteomics, genomics, clinical trials, and outcomes.

Public Health Relevance

In order to meet future public health needs of the nation this educational training program provides exceptional research training to M.D., M.D./Ph.D., or Ph.D. trainees in adult and pediatric rheumatology and clinical immunology. It will train the next generation of translational and clinical research investigators to take advantage of new breakthroughs in understanding disease pathophysiology and the resultant potential for innovative therapy in both adult and pediatric rheumatic diseases. The long-term goal is to enable the trainees to become independent investigators and academic physician- scientist leaders of the future.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Institutional National Research Service Award (T32)
Project #
5T32AR050942-08
Application #
8465743
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Program Officer
Wang, Yan Z
Project Start
2004-04-01
Project End
2016-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
8
Fiscal Year
2013
Total Cost
$352,082
Indirect Cost
$27,251
Name
Stanford University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Macaubas, Claudia; Nguyen, Khoa D; Peck, Ariana et al. (2012) Alternative activation in systemic juvenile idiopathic arthritis monocytes. Clin Immunol 142:362-72
Lin, Jack T; Stein, Emily A; Wong, Michael T et al. (2012) Differential mTOR and ERK pathway utilization by effector CD4 T cells suggests combinatorial drug therapy of arthritis. Clin Immunol 142:127-38
Levin, Aron M; Bates, Darren L; Ring, Aaron M et al. (2012) Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature 484:529-33
Frankovich, J D; Hsu, J J; Sandborg, C I (2012) European ancestry decreases the risk of early onset, severe lupus nephritis in a single center, multiethnic pediatric lupus inception cohort. Lupus 21:421-9
Macaubas, Claudia; Nguyen, Khoa; Deshpande, Chetan et al. (2010) Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states. Clin Immunol 134:206-16
Richez, Christophe; Yasuda, Kei; Bonegio, Ramon G et al. (2010) IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus. J Immunol 184:796-806
Ling, Xuefeng B; Park, Jane L; Carroll, Tanya et al. (2010) Plasma profiles in active systemic juvenile idiopathic arthritis: Biomarkers and biological implications. Proteomics 10:4415-30
Thibault, Donna L; Chu, Alvina D; Graham, Kareem L et al. (2008) IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice. J Clin Invest 118:1417-26